Pre-market Losers: Unilife Corp (NASDAQ:UNIS), Symantec Corporation (NASDAQ:SYMC), Medivation Inc (NASDAQ:MDVN), Criteo (NASDAQ:CRTO)

Unilife Corp (NASDAQ:UNIS), which is a supplier of injectable drug delivery systems located in York has recently announced the name of Dennis Pyers, its Controller to take charges as an interim CFO. Pyers will succeed the company’s previous CFO, Richard Wieland, who is moving from the role after serving for four years. The announcement comes on the heels of the company’s recent closure of debt deal with OrbiMed, wherein, it will receive $40 million immediately, followed by two $10 million funds in December and June 2015. Wieland said that as the company is sufficiently funded at present, it is an important period for Unilife Corp (NASDAQ:UNIS) to have a new CFO look after the upcoming phase. Unilife Corp (NASDAQ:UNIS) stock opened today at $5.33 and is currently trading at $5.39. The stock showed a positive weekly performance of 10.42%.

Symantec Corporation (NASDAQ:SYMC)  announced that its board of directors has appointed board member Michael Brown as interim president and chief executive officer, effective immediately. This appointment follows the termination of Steve Bennett as the company’s president and chief executive officer and his resignation from Symantec’s board of directors. A special committee of the board will immediately begin the search for a permanent CEO with the assistance of a leading executive search firm. Symantec Corporation (NASDAQ:SYMC) stock opened at $18.72, in current trading session and currently is at $18.39, by gaining 18.73%.The 52 week range of $18.36-$27.10. Company’s market capitalization is $12.72 billion.

Astellas Pharma Inc. and Medivation Inc (NASDAQ:MDVN) announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of XTANDI (enzalutamide) capsules for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy. XTANDI is currently approved for the treatment of patients with mCRPC who have previously received docetaxel chemotherapy. Medivation Inc (NASDAQ:MDVN) stock is currently trading at $68.42 .The EPS of the stock is -1.02. Company’s market capitalization is $5.22 billion.

Criteo S.A. (ADR) (NASDAQ:CRTO) announcedthat it has commenced a public offering of 5,250,000 American Depository Shares, or ADSs, each representing one of Criteo S.A. (ADR) (NASDAQ:CRTO)’s ordinary shares. Criteo SA (ADR) (NASDAQ:CRTO) stock opened the session at $42.77, and now is at $44.37. The 52 week range of the CRTO stock remained $28.27-$60.95 and the day range was $42.77-$44.30.